Editas Medicine nominates EDIT-401 as lead in vivo candidate; ~90% LDL-C reduction in NHPs

Editas Medicine, Inc.

EDIT-401 achieved ~90% mean LDL-C reduction after single dose in non-human primates across all doses (1.5-4 mg/kg), sustained for one month.
Observed at least 6-fold mean increase in LDLR protein levels; no adverse effects; transient liver enzyme increases resolved within one week.
Plans to submit IND/CTA for EDIT-401 by mid-2026 with human proof-of-concept data targeted by end of 2026.
Company re-confirmed cash runway into Q2 2027 based on existing cash and Vertex payments.
Editas will focus resources on EDIT-401 advancement; intends to identify additional target cell type by end of 2025.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.